SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as investors debate the sustainability of the AI infrastructure cycle, with community sentiment split between those viewing the stock as a long-term leader amid rumors of product delays and those frustrated by its recent underperformance compared to other semiconductor peers. While management continues to reiterate that its AI product roadmap remains intact, market participants are actively monitoring the stock for signs of institutional accumulation versus potential capitulation during a broader rotation in tech sector leadership.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is seeing significant investor attention following an unexpected Q2 delivery beat and an upward revision to its full-year vehicle delivery guidance. The community is actively debating the stock's potential for a short squeeze and long-term scaling, with bulls highlighting the R2 model as a key volume driver while bears remain focused on persistent dilution concerns and the company's path to profitability.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as market participants anticipate the upcoming release of Phase 3 durability data, which is widely considered a critical catalyst for the company's rolling NDA submission. Community discourse remains heavily focused on the drug's first-mover advantage, potential for a high-value acquisition, and the positive regulatory tailwinds recently bolstered by government directives to fast-track psychedelic research.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened community engagement driven by intense short interest of over 40% and significant call option activity, leading many investors to monitor the stock for a potential squeeze. While some traders are focused on technical resistance levels and recent merger updates as potential catalysts, others remain cautious of the stock's volatility and historical price patterns.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate the company's transition into an enterprise-wide agentic AI orchestration layer, with community sentiment deeply split between those highlighting the massive short interest as a potential squeeze catalyst and skeptics focused on persistent price stagnation. Bulls are pointing to the company's GAAP profitability and cash-rich balance sheet as reasons to buy the dip, while others express frustration over the stock's inability to sustain momentum despite positive fundamental developments.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant momentum and volatility as investors react to positive FDA briefing documents regarding its mRNA flu vaccine candidate ahead of a key advisory committee vote. The community is actively debating the stock's long-term growth potential through its expanding oncology pipeline while tracking high short interest that has fueled speculation of a potential short squeeze.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is experiencing intense market activity following a ten-billion-dollar acquisition agreement by Vertex Pharmaceuticals, a move that provides a significant premium to shareholders. The community is actively celebrating the buyout while discussing the potential for a sector-wide rotation into similar biotech growth plays and debating whether to hold positions or rotate capital.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following a transformative deal with Anthropic, featuring a 20-year data center lease expected to generate significant long-term revenue. While the stock has seen volatile price action, the community is heavily debating the company's shift from a Bitcoin mining focus to a core AI infrastructure provider, with many investors maintaining bullish long-term sentiment despite recent short-term market fluctuations.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is trending as investors focus on its recently secured U.S. patent for edge-native AI autonomy and its strategic inclusion in Department of War exercises like Northern Strike 26-2. Community discussion is heavily centered on the company's SwarmOS and Gremlin-X technology as a potential disruptor in autonomous defense systems, with many participants actively debating its long-term potential as a defense prime versus the impact of ongoing short interest.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is drawing heavy interest as analysts praise its pivotal role in the AI-native economy and SASE sector, leading to increased price targets and bullish sentiment. Community discussions are centered on the stock's consolidation patterns near all-time highs and its strategic positioning as essential infrastructure for managing agentic AI traffic.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results PR Newswire JILIN, China, April...

Regulatory Wins, Capital Flows, and Global Expansion Drive Market Momentum

A wave of regulatory clarity, strategic financing, and global expansion is reshaping pockets of the market, with companies across biotech, mobility, and emerging healthcare infrastructure positioning for outsized growth. $MGRX, $TOVX, $ZYBT, $FFAI, $TGNT

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Sees Large Decline in Short Interest

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT - Get Free Report) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totaling...

Zhengye Biotechnology (NASDAQ:ZYBT) Trading Up 2.8% - What's Next?

Zhengye Biotechnology (NASDAQ:ZYBT) Stock Price Up 2.8% - Should You Buy...

Zhengye Biotechnology Holding Ltd. engages in the manufacture and sale of veterinary vaccines. It offers a range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company was founded on March 24, 2023 and is headquartered in Jilin City, China.

Zhengye Biotechnology Holding Ltd. - Ordinary Shares - Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

ZYBTZhengye Biotechnology Holding Ltd

Latest ZYBT News